A 72-year-old woman with mild cognitive impairment due to Al…
A 72-year-old woman with mild cognitive impairment due to Alzheimer’s disease (MMSE 24/30) undergoes PET imaging confirming the presence of amyloid plaques. Her family asks about newly approved disease-modifying therapies. Which of the following monoclonal antibodies targeting amyloid-beta has been approved by the FDA and has demonstrated slowing of cognitive decline in early Alzheimer’s disease?